A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Huntington Disease

In brief

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Key facts

Study ID
NCT05358717
Run by
Novartis Pharmaceuticals
People needed
159
Starts
2022-06-03
Expected to finish
2025-07-31
Last updated by the study team
2026-06-16

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.